<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574663</url>
  </required_header>
  <id_info>
    <org_study_id>TGR-1202-102 (RM-404)</org_study_id>
    <nct_id>NCT02574663</nct_id>
  </id_info>
  <brief_title>TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TG Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TG Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a
      single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients
      with select relapsed or refractory solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TGR-1202 will be evaluated alone or in combination with nab-paclitaxel + gemcitabine or with
      FOLFOX in patients with adenocarcinoma of the pancreas, adenocarcinoma of the colon, rectum,
      gastric and GE junction cancer, and GI Stromal Tumor (GIST) who have relapsed from or are
      refractory to prior treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events as a measure of safety and tolerability of TGR-1202 as a single agent and in combination in combination with nab-paclitaxel + gemcitabine, or with oxaliplatin + leucovorin + 5-FU (FOLFOX) or with FOLFOX + bevacizumab.</measure>
    <time_frame>Up to 28 days after the last patient enrolled</time_frame>
    <description>To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Overall response rate with TGR-1202 as a single agent and in combination with nab-paclitaxel + gemcitabine, or with oxaliplatin + leucovorin + 5-FU (FOLFOX) or with FOLFOX + bevacizumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Duration of response with TGR-1202 as a single agent and in combination with nab-paclitaxel + gemcitabine, or with oxaliplatin + leucovorin + 5-FU (FOLFOX) or with FOLFOX + bevacizumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile of TGR-1202. Peak Plasma Concentration (Cmax).</measure>
    <time_frame>At selected timepoints up through 6 months</time_frame>
    <description>This endpoint will measure the plasma PK profile of TGR-1202 as a single agent and in combination with nab-paclitaxel + gemcitabine, or with oxaliplatin + leucovorin + 5-FU (FOLFOX) or with FOLFOX + bevacizumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile of TGR-1202. Time to Peak Plasma Concentration (Tmax).</measure>
    <time_frame>At selected timepoints up through 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile of TGR-1202. Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>At selected timepoints up through 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Rectal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Gastrointestinal Stromal Tumor (GIST)</condition>
  <arm_group>
    <arm_group_label>TGR-1202</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TGR-1202 daily dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TGR-1202 + nab-paclitaxel + gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TGR-1202 oral daily dose + nab-paclitaxel + gemcitabine both as an IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TGR-1202 + FOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TGR-1202 + FOLFOX + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen) + bevacizumab IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TGR-1202</intervention_name>
    <description>TGR-1202 oral daily dose</description>
    <arm_group_label>TGR-1202</arm_group_label>
    <arm_group_label>TGR-1202 + nab-paclitaxel + gemcitabine</arm_group_label>
    <arm_group_label>TGR-1202 + FOLFOX</arm_group_label>
    <arm_group_label>TGR-1202 + FOLFOX + Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel + gemcitabine</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>TGR-1202 + nab-paclitaxel + gemcitabine</arm_group_label>
    <other_name>Abraxane (nab-paclitaxel) + Gemzar (gemcitabine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin + Folinic acid + Fluorouracil</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>TGR-1202 + FOLFOX</arm_group_label>
    <other_name>Eloxatin (Oxaliplatin) + Leucovorin (Folinic acid) + 5-FU (Fluorouracil)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab</intervention_name>
    <description>IV Infusion</description>
    <arm_group_label>TGR-1202 + FOLFOX + Bevacizumab</arm_group_label>
    <other_name>Eloxatin (Oxaliplatin) + Leucovorin (Folinic acid) + 5-FU (Fluorouracil) + Avastin (Bevacizumab)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed:

               1. adenocarcinoma of the pancreas (pancreatic cancer)

               2. adenocarcinoma of the colon or rectum (colorectal cancer)

               3. adenocarcinoma of the gastric (gastric cancer)

               4. esophageal cancer

               5. gastrointestinal stromal tumor (GIST)

          -  Relapsed or refractory disease

          -  Measurable lesion by RECIST 1.1

        Exclusion Criteria:

          -  Known Hepatitis B, C or HIV infection

          -  Previous therapy with any drug that inhibits the PI3K pathway

          -  Anti-tumor therapy within 21 days of study Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna Bendell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sarah Cannon Research Instititue (SCRI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TG Therapeutics Trial Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

